RSV Immunisation Pathfinder 1.0 Evaluation

In 2024, an RSV Immunisation Pathfinder Programme was established to offer nirsevimab to all infants born between 1st September 2024 and 28th February 2025, as well as other clinically high-risk infants less than 12 months of age. The aim of the programme was to reduce RSV-related illness among young infants.

Following completion of the programme, a multi-disciplinary working group convened by the National Health Protection Office (NHPO) carried out an evaluation to assess the effectiveness and efficiency of the RSV Immunisation Pathfinder Programme in Ireland, to inform future RSV immunisation policy.